Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
Lola Sepot-Boucherit, Director Rare Bleeding Disorders at Novo Nordisk, shared a post on LinkedIn:
“Under brilliant Parisian sunshine, the City of Light became a catalyst for scientific exchange, collaboration and innovation at ISTH.
It was a privilege to welcome the global haemostasis community to France and to engage with researchers and healthcare professionals from around the world. Throughout the week, the science on display highlighted how rapidly our field is evolving.
For Novo Nordisk, the congress of the International Society on Thrombosis and Haemostasis (ISTH) also reflected the exciting new chapter we are entering in rare diseases.
As we accelerate research and scientific innovation, the engagement of our Executive Management, including Hong Chow, reinforced our long-term commitment and ambition to help reimagine the future of care for people living with rare bleeding disorders.
It was also a real pleasure to welcome so many Novo Nordisk colleagues to Paris, share a little of the French art de vivre, and spend this memorable week alongside our amazing French team.
See you next year in Vancouver!”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring